Company Profile
Azurity
Profile date: 2026-10-07
Azurity Pharmaceuticals
Azurity Pharmaceuticals, Inc. is a privately held specialty pharmaceutical company headquartered in Woburn, Massachusetts, USA. The entity specializes in identifying and addressing the unique dosage-form needs of underserved patient populations. Azurity focuses on developing, manufacturing, and commercializing FDA-approved specialty medicines—primarily liquid formulations, convenient oral suspensions, and ready-to-use delivery systems—for patients who have difficulty swallowing solid oral dosage forms (dysphagia) or who require precise dose titrations, such as pediatric, geriatric, and chronically ill patients.
Core Mission and Focus Areas
Azurity operates on the principle of transforming existing proven active pharmaceutical ingredients (APIs) into specialized, user-friendly dose forms. By creating stable, standardized, pre-formulated liquid or convenient alternatives, Azurity eliminates the need for non-FDA-approved extemporaneous compounding or crushing of tablets, thereby reducing dosage variability, administrative complexity, and safety risks.
The company's commercial and clinical focus spans multiple therapeutic areas across more than 50 countries, including: - Endocrinology and Metabolic Disorders - Cardiovascular Health and Hypertension - Central Nervous System (CNS) and Neurology - Gastroenterology - Oncology and Antiemetic Care - Pediatrics and Rare Diseases
Products and Therapeutic Portfolio
Azurity Pharmaceuticals maintains an extensive commercial portfolio of FDA-approved prescription medicines designed to meet specific dose-form and delivery challenges:
1. Endocrinology and Diabetes
- BRYNOVIN (sitagliptin oral liquid): The first and only FDA-approved oral liquid formulation of sitagliptin, designed for adults with type 2 diabetes mellitus who require glycemic control but struggle with swallowing solid tablets.
- ARYNTA (lisdexamfetamine dimesylate oral solution): An FDA-approved liquid formulation of lisdexamfetamine indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older, as well as moderate to severe Binge Eating Disorder (BED) in adults.
2. Cardiovascular and Antihypertensive Care
- EPANED (enalapril maleate oral solution): A ready-to-use liquid ACE inhibitor used for treating hypertension and heart failure in pediatric and adult patients.
- JAVADIN (clonidine hydrochloride oral solution): A liquid oral formulation of clonidine indicated for treating hypertension in adult patients who require liquid delivery.
- QBRELIS (lisinopril oral solution): An oral liquid ACE inhibitor formulation providing precise dosing for hypertension in adults and children aged 6 and older.
- KATERZIA (amlodipine oral suspension): An oral suspension of amlodipine providing convenient liquid dosing for pediatric and adult hypertension.
3. Neurology and Central Nervous System
- ZONISADE (zonisamide oral suspension): A ready-to-use oral liquid formulation of zonisamide indicated as adjunctive therapy in the treatment of partial-onset seizures in adults and pediatric patients.
- EPRONTIA (topiramate oral solution): An FDA-approved oral liquid topiramate formulation indicated for seizure treatment and migraine prevention.
4. Gastroenterology
- KONVOMEP (omeprazole and sodium bicarbonate for oral suspension): An FDA-approved oral liquid proton pump inhibitor (PPI) indicated for active benign gastric ulcers and the reduction of risk of upper gastrointestinal bleeding in critically ill adult patients.
- GOLYTELY / NULYTELY (polyethylene glycol 3350 and electrolytes for oral solution): Established prescription bowel preparations for gastrointestinal cleansing prior to endoscopic or radiological procedures.
5. Oncology and Supportive Care
- XATMEP (methotrexate oral solution): The first FDA-approved pediatric oral liquid methotrexate, indicated for pediatric acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA).
- Aprepitant Injectable Emulsion: A ready-to-use intravenous antiemetic formulation designed to prevent chemotherapy-induced nausea and vomiting (CINV).
6. Metabolic and Weight Management Assets
- CONTRAVE (naltrexone HCl / bupropion HCl): Added to Azurity's portfolio to expand therapeutic options for chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity.
Services and Patient Support Programs
In addition to developing specialized pharmaceutical formulations, Azurity offers comprehensive healthcare support services aimed at improving patient adherence, affordability, and provider access:
1. Azurity Solutions Patient Access Platform
Azurity operates dedicated support channels (Azurity Solutions) to help eligible commercial patients navigate insurance coverage, copay assistance, and pharmacy distribution: - Copay Assistance Programs: Providing financial support initiatives (e.g., $5 copay cards for eligible commercial patients) to ensure access to brand-name liquid formulations. - Pharmacy Fulfillment Networks: Coordinating distribution across over 70,000 retail, specialty, and long-term care pharmacies nationwide.
2. Healthcare Professional (HCP) & Institutional Support
- Medical Information Services: Delivering clinical data, stability information, and administration guidelines to hospital systems, long-term care facilities, and pediatric clinics.
- Compounding Alternative Education: Educating clinicians and pharmacists on the safety, consistency, and regulatory benefits of standardized, FDA-approved dose-form medicines over extemporaneously compounded liquids.
3. Partnering and Licensing Capabilities
Azurity actively collaborates with biotechnology firms, drug developers, and international specialty pharma companies through licensing, co-development, and distribution partnerships (such as commercialization agreements for novel drug delivery platforms and specialized antiemetic treatments) to expand access to patient-ready medicines globally.